-+ 0.00%
-+ 0.00%
-+ 0.00%

Aspire Biopharma secures commitment letter for up to $22.5 million DCS acquisition loan

PUBT·04/20/2026 12:31:30
Listen to the news
Aspire Biopharma secures commitment letter for up to $22.5 million DCS acquisition loan
  • Aspire Biopharma entered a letter of intent dated April 15, 2026 to buy Dura Control Systems (DCS) for USD 30 million in cash.
  • DCS is described as a global automotive driver control systems supplier with FY2025 revenue above USD 200 million.
  • DCS delivered more than USD 20 million of adjusted EBITDA on that revenue base, on an unaudited basis.
  • Aspire secured a commitment letter for a senior secured credit facility of up to USD 22.5 million to finance the proposed acquisition.
  • Facility is structured as a five-year term loan priced at 325 basis points over one-month term SOFR.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202604200830ACCESSWRNAPR_____1158888) on April 20, 2026, and is solely responsible for the information contained therein.